penicillanic acid has been researched along with Febrile Neutropenia in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 19 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alp, E; Çetin, M; Elmali, F; Kaynar, L; Kürkçüoglu, CA; Metan, G; Yozgat, N | 1 |
| Hori, D; Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D | 1 |
| Hahn, U; Lipman, J; Peake, SL; Roberts, JA; Roberts, MS; Sime, FB; Tiong, IS; Warner, MS | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Leong, D; Wu, PE | 1 |
| Bergstrom, C; Gupta, A; Nagalla, S | 1 |
| Arda, B; Nazli-Zeka, A; Ozkoren-Calik, S; Pullukcu, H; Sipahi, H; Sipahi, OR; Tasbakan, M; Ulusoy, S; Yamazhan, T | 1 |
| Acipayam, C; Bayram, I; Ozkan, A; Sezgin, G; Tanyeli, A | 1 |
| Kishimoto, K; Kobayashi, K; Kobayashi, R; Sano, H; Suzuki, D; Yasuda, K | 1 |
| Bae, EY; Cho, B; Chung, NG; Han, SB; Jeong, DC; Jung, SW; Kang, JH; Kim, HK; Lee, DG; Lee, JW; Park, YJ | 1 |
| Abu-Seir, H; Gregg, KS; Hough, SM; Marini, BL; Nagel, JL | 1 |
| Akiyama, N; Kanda, Y; Saito, M; Tamura, K | 1 |
| Emiroğlu, M; Köksal, Y; Köse, D | 1 |
| Aamir, M; Abrol, P; Punia, H; Sharma, D | 1 |
| Huang, W; Jing, Y; Li, J; Wang, Q; Yu, L; Yuan, L; Zhao, X; Zhou, D | 1 |
| Aynioglu, A; Hacihanefioglu, A; Mutlu, B | 1 |
| Gustinetti, G; Mikulska, M | 1 |
| Atalay, MA; Demir, K; Demiraslan, H; Doganay, M; Eren, E; Kaynar, L; Koc, AN | 1 |
| Chai, LY; Chee, YL; Chng, WJ; Ding, Y; Hsu, LY; Jin, J; Lee, YM; Poon, LM; Tan, LK | 1 |
1 review(s) available for penicillanic acid and Febrile Neutropenia
| Article | Year |
|---|---|
Bloodstream infections in neutropenic cancer patients: A practical update.
Topics: Anti-Bacterial Agents; Bacteremia; Cefepime; Cephalosporins; Disease Management; Drug Resistance, Bacterial; Febrile Neutropenia; Fluoroquinolones; Gram-Negative Bacteria; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pre-Exposure Prophylaxis; Risk Factors | 2016 |
5 trial(s) available for penicillanic acid and Febrile Neutropenia
| Article | Year |
|---|---|
Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients.
Topics: Adolescent; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Child; Child, Preschool; Febrile Neutropenia; Female; Humans; Immunoglobulins, Intravenous; Infant; Infant, Newborn; Male; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Thienamycins; Treatment Outcome; Young Adult | 2018 |
Comparison between piperacillin/tazobactam and cefepime monotherapies as an empirical therapy for febrile neutropenia in children with hematological and malignant disorders: A prospective, randomized study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Infant; Infant, Newborn; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Young Adult | 2015 |
A clinical evaluation of efficacy and safety of cefepime monotherapy versus piperacillin-tazobactam in patients of paediatric age group with febrile neutropenia in a tertiary care centre of north India.
Topics: Adolescent; Anti-Bacterial Agents; Bacterial Infections; Cefepime; Cephalosporins; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Fever; Humans; India; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Tertiary Care Centers; Treatment Outcome | 2016 |
Piperacillin-tazobactam vs. imipenem-cilastatin as empirical therapy in hematopoietic stem cell transplantation recipients with febrile neutropenia.
Topics: Adult; Anti-Bacterial Agents; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Febrile Neutropenia; Female; Follow-Up Studies; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Risk Factors | 2016 |
A comparison of the efficacy of piperacillin-tazobactam and cefoperazone-sulbactam therapies in the empirical treatment of patients with febrile neutropenia.
Topics: Adult; Aged; Antineoplastic Agents; Cefoperazone; Drug Combinations; Drug Eruptions; Febrile Neutropenia; Female; Hematologic Neoplasms; Humans; Leukocyte Count; Male; Middle Aged; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Sulbactam; Treatment Outcome; Young Adult | 2016 |
13 other study(ies) available for penicillanic acid and Febrile Neutropenia
| Article | Year |
|---|---|
A change for the antibacterial treatment policy to decrease carbapenem consumption at a haematopoietic stem cell transplantation centre.
Topics: Amikacin; Anti-Bacterial Agents; Carbapenems; Cross Infection; Febrile Neutropenia; Guidelines as Topic; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Penicillanic Acid; Piperacillin; Retrospective Studies; Tazobactam; Teicoplanin; Tertiary Care Centers; Treatment Outcome; Turkey; Vancomycin | 2017 |
Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
Topics: Aged; Anti-Bacterial Agents; Bacterial Infections; Creatinine; Febrile Neutropenia; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Acute Kidney Injury Due to Concomitant Vancomycin and Piperacillin-Tazobactam.
Topics: Acute Kidney Injury; Febrile Neutropenia; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 2018 |
Acute Kidney Injury Due to Concomitant Vancomycin and Piperacillin-Tazobactam-Reply.
Topics: Acute Kidney Injury; Febrile Neutropenia; Humans; Penicillanic Acid; Piperacillin; Tazobactam; Vancomycin | 2018 |
Piperacillin/tazobactam vs. cefoperazone/sulbactam in adult low-risk febrile neutropenia cases.
Topics: Anti-Bacterial Agents; Cefoperazone; Drug Combinations; Febrile Neutropenia; Female; Humans; Male; Middle Aged; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Retrospective Studies; Sulbactam; Treatment Outcome | 2014 |
Meropenem versus piperacillin-tazobactam as empiric therapy for febrile neutropenia in pediatric oncology patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Drug Therapy, Combination; Febrile Neutropenia; Female; Humans; Infant; Male; Meropenem; Neoplasms; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Thienamycins; Young Adult | 2014 |
Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in febrile neutropenic children.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Cefepime; Cephalosporins; Child; Escherichia coli; Escherichia coli Infections; Febrile Neutropenia; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies | 2015 |
Risk factors for piperacillin/tazobactam-resistant Gram-negative infection in hematology/oncology patients with febrile neutropenia.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Case-Control Studies; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Hematologic Neoplasms; Humans; Male; Middle Aged; Neoplasms; Penicillanic Acid; Penicillin Resistance; Piperacillin; Piperacillin, Tazobactam Drug Combination; Retrospective Studies; Risk Factors; Young Adult | 2015 |
Efficacy and safety of tazobactam/piperacillin as an empirical treatment for the patients of adult and child with febrile neutropenia in Japan.
Topics: Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Febrile Neutropenia; Female; Fever; Humans; Infant; Japan; Leukocyte Count; Male; Middle Aged; Neutrophils; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Young Adult | 2015 |
High-risk febrile neutropenia and its management in children with solid tumors and lymphoma.
Topics: Amikacin; Anti-Bacterial Agents; C-Reactive Protein; Calcitonin; Calcitonin Gene-Related Peptide; Child; Febrile Neutropenia; Female; Humans; Imipenem; Lymphoma; Male; Neoplasms; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Protein Precursors | 2015 |
Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia.
Topics: Anti-Bacterial Agents; Antigens, Fungal; False Positive Reactions; Febrile Neutropenia; Female; Galactose; Humans; Invasive Pulmonary Aspergillosis; Male; Mannans; Microbiological Techniques; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination | 2017 |
Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital.
Topics: Academic Medical Centers; Adult; Bacteremia; Carbapenems; Ceftazidime; Drug Resistance, Multiple; Febrile Neutropenia; Female; Gram-Negative Bacteria; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Prevalence; Prospective Studies; Risk Factors; Sepsis; Singapore; Tazobactam; Treatment Outcome; Universities | 2012 |